ProCE Banner Activity

Dosing, Administration, and Risks/Benefits of Treatment Strategies for UC: A Patient’s Perspective

Multimedia
Join us for an interactive presentation by Kaitlyn Francese, MSN, RN, OCN, discussing the risks and benefits of urothelial cancer treatments from the perspectives of the healthcare professional and the patient.

Released: May 28, 2021

Expiration: May 27, 2022

Share

Faculty

Arjun Balar

Arjun Balar, MD

Associate Professor of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Kaitlyn Francese

Kaitlyn Francese, MSN, RN, OCN

Senior Nurse Clinician
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Pfizer and EMD Serono

Learning Objectives

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence and patient and disease characteristics
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors

Faculty Disclosure

Primary Author

Arjun Balar, MD

Associate Professor of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Arjun Balar, MD, has disclosed that he has received consulting fees from AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Immunomedics/Gilead, Incyte, Istari Oncology, Janssen, Merck, Nektar, Pfizer, and Seagen; has received funds for research support to his institution from AstraZeneca/MedImmune, Genentech, Immunomedics, Merck, Nektar, and Seagen; has received funds for non-CME/CE services from AstraZeneca/MedImmune, EpiVax Oncology, Genentech, Merck, and Nektar; and owns stock in EpiVax Oncology.

Kaitlyn Francese, MSN, RN, OCN

Senior Nurse Clinician
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Kaitlyn Francese, RN, has disclosed that she has received consulting fees from Seagen/Astellas.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to disclose.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to disclose.